TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
Transforming Growth Factor beta (TGF-β) is a pleiotropic cytokine produced in large amounts within cancer microenvironments that will ultimately promote neoplastic progression, notably by suppressing the host’s T-cell immunosurveillance. This effect is mostly due to the well-known...
Main Authors: | Amina Dahmani, Jean-Sébastien Delisle |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/10/6/194 |
Similar Items
-
NK Cell Metabolism and TGFβ – Implications for Immunotherapy
by: Karen Slattery, et al.
Published: (2019-12-01) -
Advances in Immunotherapy and the TGF-β Resistance Pathway in Metastatic Bladder Cancer
by: David J. Benjamin, et al.
Published: (2021-11-01) -
Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer
by: Shuping Yin, et al.
Published: (2023-10-01) -
Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy
by: Angélique Vienot, et al.
Published: (2022-12-01) -
TGF-β Signaling and Resistance to Cancer Therapy
by: Maoduo Zhang, et al.
Published: (2021-11-01)